Clinical Trial Studies Drug for Overactive Bladder F


Participants first take Detrol LA® n MIchael guralNIck, MD


roedtert & The Medical College of Wisconsin are participating in a nationwide clinical trial aimed at determining if a drug, Sanctura XR®


, treats overactive bladder more effectively than a more commonly prescribed medication. Overactive bladder – a sudden urge to urinate resulting in leakage or wetting – is a condition that


affects an estimated 30 million people nationwide. It differs from stress incontinence, in which coughing or sneezing causes a urine leak.


“Sanctura has very few, if any, interactions with other drugs, so participants are those who take at


least five other medications and/or supplements for other medical issues.” said Michael Guralnick, MD, principal investigator and a Medical College of Wisconsin urologist.


daily for one month, then take Sanctura XR® daily for the


remainder of the 19-week trial, sponsored by Allergan Inc., the pharmaceutical company that manufactures Sanctura XR®


. Participants must keep a daily record of their urination habits during the trial. “Overactive bladder typically affects women and older adults,” said Dr. Guralnick. “Depending


on the severity, some people are afraid to leave their homes, can experience skin conditions, sleep deprivation or bone fractures caused by falls when rushing to the bathroom.” n


Yondelis®


Trials Look at Recurrent Soft Tissue Sarcoma Drug T


In this trial, two-thirds of the patients will receive Yondelis® They must have been previously treated with Adriamycin®


wo clinical trials at Froedtert & The Medical College of Wisconsin are for patients who need further treatment for soft tissue sarcoma, a cancer that occurs in fat, muscle, cartilage and bone. Both study , a drug not available in the United States outside of clinical trials.


Medical College of Wisconsin oncologist and principal investigator of the trial. The study is for patients who have advanced or metastatic sarcoma, and were previously treated with the medications Adriamycin®


therapy. Froedtert & The Medical College are the only site in the state participating in the national trial. The second clinical trial is open to patients with other types of sarcoma than those in the first study.


, and all patients will receive Yondelis® . “We don’t have a wide enough range of treatments for sarcoma, and this drug could be one more potential


tool,” Dr. Charlson said. “This study will help determine if the drug is effective enough to receive Food and Drug Administration approval.” n


U.S. News & World Report Ranks Froedtert in 12 Specialties DON’T MISS the Living with Sarcoma event Wednesday, Feb. 29; see the My Health supplement for details.


F qual i ty


roedtert & The Medical College of Wisconsin were ranked in a total of 12 specialty areas in U.S. News & World Report’s 2011-12 “Best Hospitals” list.


Froedtert & The Medical College received national ranking in diabetes and endocrinology; ear,


nose and throat; gastroenterology; nephrology; and pulmonology, and were ranked a regional high performer in cancer; cardiology and heart surgery; geriatrics; gynecology; neurology and neurosurgery; orthopedics; and urology.


Froedtert & The Medical College are the only adult hospital in Milwaukee to receive these national


rankings, placing them in the top 50 hospitals in the nation for those specialties. Froedtert & The Medical College also rank as the top hospital in metropolitan Milwaukee.


The national rankings, annually published by U.S. News for more than 20 years, are widely considered the most authoritative


hospital guide. Of the nearly 5,000 hospitals evaluated in 16 different specialties, only 140 performed well enough to rank in even one specialty. n


froedtert.com Froedtert Today January 2012 5


The first trial specifically targets liposarcoma and leiomyosarcoma, according to John Charlson, MD, a and ifosfamide.


while one-third will receive another, standard


n jOhN charlSON, MD


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16